Browse By: Country ι Category ι Tag
Home  »  Assessment Group

Assessment Group Market Research Reports

Established in 2001, the Assessment Group is the market leader in clinical practice pattern assessments of healthcare professionals, and in measuring the impact of messages on their performance. Our scientifically-validated methods and research techniques make us unique and allows to provide comprehensive clinical analytics for optimizing initiatives, demonstrating value, and ultimately enhancing patient health.

US Market Changes in the Treatment of Advanced Prostate Cancer
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 to compare oncology practice patterns and determine trends across time in the management of advanced prostate cancer. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing U.S. oncologists on the treatment of patients with advanced prostate cancer.
Published Date: Sep 2012
Published By: Assessment Group

Price: $2900
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkins lymphoma. A survey with unfolding patient case scenarios was presented to 158 U.S. oncologists for their open-ended responses to questions concerning their choices of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 using parallel cases to determine trends across time and changes in practice patterns in the management of non-Hodgkins lymphoma.
Published Date: Sep 2012
Published By: Assessment Group

Price: $2900
US Market Changes in the Treatment of Advanced Melanoma
Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the factors that influence those decisions. Data presented includes oncologist treatment regimen choices, factors that influence their decisions, barriers to optimal patient care and confidence in patient treatment.  This report identifies market changes based on a comparison of physician practice patterns from 2011 and 2012 and provides actionable data for developing marketing strategies.
Published Date: Sep 2012
Published By: Assessment Group

Price: $2900
US Market Changes in the Treatment of Advanced Breast Cancer
A survey with unfolding patient case scenarios was presented to 180 U.S. oncologists who manage patients with metastatic breast cancer for their open-ended responses. In each case, oncologists were asked to respond to questions concerning their choices of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients.  This survey was conducted in 2011 and 2012 to determine trends across time and changes in practice patterns in the management of advanced breast cancer.
Published Date: Sep 2012
Published By: Assessment Group

Price: $2900
US Market Changes in the Treatment of Advanced Lung Cancer
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal practice patterns of oncologists. Progressively unfolding patient case scenarios were presented to 152 U.S. oncologists for their responses to open-ended questions concerning their choices of treatment regimens, factors that influence their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients.  This report examines the market for therapeutics by comparing oncology practice patterns in the treatment of advanced lung cancer in 2011 and 2012.
Published Date: Sep 2012
Published By: Assessment Group

Price: $2900
Optimizing Treatment for Bone Metastases in Patients with Advanced Cancers
Understand current practice patterns related to bone metastases in patients with advanced cancers. Patient specific unfolding case scenarios presented to 174 high-prescribing oncologists on the treatment of bones metastases in patients with advanced stages of cancer including breast, renal cell carcinoma, and prostate. The survey was presented for their responses on clinical decisions. Oncologists were asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influence their decisions, and barriers to optimal patient management. The survey was administered electronically by Qualtrics survey software between December 15, 2010 and March 31, 2011. Patient progression reveals decisions in treatment throughout patient stages. Patient case hig
Published Date: Oct 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma
Patient specific case scenario on advanced non-Hodgkin’s lymphoma in a situation involving a patient with Stage IIIA Asymptomatic Indolent Lymphoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphoma.  Treatment decisions for advanced stage
Published Date: Apr 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
Two patient specific case scenarios on advanced non-Hodgkin’s lymphoma involving patients with a) relapsed large cell lymphoma and b) large cell lymphoma with compromised cardiac function that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal:   Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphom
Published Date: Apr 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin\'s Lymphoma
A patient specific case scenario on advanced non-Hodgkin’s lymphoma involving a patient with stage IV follicular B-cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal:   Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphoma.  Treatment decisions for advanced stages of cancer are diff
Published Date: Apr 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin\'s Lymphoma
Experience real patient situations that progressively unfold, presented to a representative sample of 158 US oncologists who manage 11 or more patients monthly with non-Hodgkin’s lymphoma. Oncologists were presented with four patient case scenarios and asked to respond to open-ended questions concerning their choices of treatment regimens, factors that influenced their decisions, and barriers to optimal patient management. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types. Patient situations: Asymptomatic indolent lymphoma Elderly infirm patient with advanced follicular lymphoma Relapsed large cell lymphoma and Large cell lymphoma
Published Date: Apr 2011
Published By: Assessment Group

Price: $8900
Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists\' Survey
A patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals: Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal care Confidence in treatment. Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.  Treatment decisions for advanced stages of lung cancer are difficult to track as information quickly ch
Published Date: Apr 2011
Published By: Assessment Group

Price: $2999
Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists\' Survey
A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals: Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer. Treatment decisions for advanced stages of lung cancer are difficult to track as
Published Date: Apr 2011
Published By: Assessment Group

Price: $2999
Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma: Clinical Insights from a US Oncologists\' Survey
A patient specific case scenario on advanced lung cancer in a situation involving a patient that is a light smoker with lung adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:   Decisions in treatment and tests through disease stages Factors influencing their decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.  Treatment decisions for advanced stages of lung cancer are
Published Date: Apr 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer
Experience real patient situations that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced lung cancer.  Case highlights include: Smoker with squamous cell carcinoma Light smoker with adenocarcinoma Nonsmoker with adenocarcinoma Former light smoker whose cancer is EGFR positive Treatment decisions for advanced
Published Date: Apr 2011
Published By: Assessment Group

Price: $8900
Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists\' Survey
Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.  This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer.  Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports
Published Date: Mar 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer
Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.  Case highlights include: Rising PSA in a patient without documented metastatic disease Asymptomatic castration resistant metastatic disease Symptomatic metastatic disease Symptomatic disease in an elderly patient Treatme
Published Date: Mar 2011
Published By: Assessment Group

Price: $8900
Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists\' Survey
Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.  This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer.  Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports
Published Date: Mar 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer
Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.  Primary research for the oncology prescribing data that you are missing, directly from high-prescribing US oncologists: what they prescribe, when, and why. Case highlights include:   Older patient with retroperitoneal adenopathy and small lung nodules Anemic patient with extremely high LDH levels Patient with multiple comorbidities including heart and lung disease P
Published Date: Feb 2011
Published By: Assessment Group

Price: $6900
Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their open responses on specific clinical decisions.  Patient progression reveals: Decisions in treatment throughout patient stages Factors influencing their decisions Barriers to optimal care Confidence in treatment. Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Negative Metastatic Breast Cancer.  Treatment decisions for advanced stages of brea
Published Date: Jan 2011
Published By: Assessment Group

Price: $2999
Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
Primary research that presents a patient specific case scenario unfolding throughout the report, to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on specific clinical decisions.  Patient progression reveals: Decisions in treatment throughout patient stages Factors influencing their decisions Barriers to optimal care Confidence in treatment. Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Triple Positive Metastatic Breast Cancer.  Treatment decisions for advanced stages of brea
Published Date: Jan 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer
Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.  Patient case highlights:  In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choos
Published Date: Jan 2011
Published By: Assessment Group

Price: $2999
US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.  Primary research on the oncology prescribing data that you are missing, directly from high-prescribing US oncologists regarding metastatice breast cancer: what they prescribe, when, and why. Case highlights include:   Triple negative metastatic breast cancer Triple positive metastatic breast cancer ER/PR positive HER2neu negative metastatic breast cancer Metast
Published Date: Jan 2011
Published By: Assessment Group

Price: $8900

Back To Top